Cancer IVD Market size was valued at $17,728 million in 2020 and is anticipated to reach $22,430 million by the end of 2026 growing at a CAGR of 6.0% during the forecast period 2021-2026. The surgical electrical stapler’s industry growth rate is attributed to the rising incidences of chronic lifestyle diseases across the globe and is anticipated to bring new opportunities. Cancer In vitro diagnostics (IVD) are medical devices, which require the use of assays and reagents to diagnose a medical condition. Moreover, these instruments analyze body fluids and tissue samples that are collected from a patient.
In addition, there are a variety of in vitro diagnostic instruments that work with various techniques such as immunodiagnostics, tissue diagnostics, hematology, and molecular diagnostics. Surgical staplers are instruments used to aid in the physical modification of biological tissue or the rapid recovery of internal and external body tissues. Furthermore, developments in genomics and proteomics, as well as increased investment in developing countries are bringing a new range of condition-specific markers and tests to market.
On the contrary, inadequate returning policy and stringent regulatory approval framework are restraining the growth of this market. Nonetheless, ongoing research and development in the healthcare sector coupled with advancement in medical technologies is anticipated to open growth avenues for the Cancer IVD market during the forecast period 2021-2026.
Report Coverage
Key Takeaways
- North America dominated the Cancer IVD market with a share of 35.60% in the year 2020.
- The factors such as growing aging population and increasing usage of point-of-care testing and personalized medicine are among the major factor projected to impel growth of Cancer IVD market.
- Additionally, factors such as development of automated in vitro diagnostic systems for laboratories and hospitals to provide efficient, accurate, and error-free diagnosis are set to create opportunities paving a way for the growth in the market during forecast period 2021-2026.
Cancer IVD Market Segment Analysis - By Product & Services
In 2020, on the basis of product and services, reagents segment accounted for the largest segmental revenue of the Cancer IVD market. The reagents segment held the largest market on account of the fact that there is an increasing demand for rapid, accurate, and sensitive devices. Furthermore, their wide usage in cancer in-vitro diagnostic testing, increase in demand for self-testing and point-of-care products, and rise in the number of R&D initiatives pertaining to reagents are expected to aid market growth.
On the contrary, services segment is projected to witness healthy growth throughout the forecast period 2021-2026 with a CAGR of 6.80% as a result of the various programming interfaces used for operating cancer diagnostic instruments, conducting analysis, and interpreting results. Many instruments, including point-of-care analyzers, laboratory-based analyzers, portable personal in vitro diagnostics, and others, use in vitro diagnostic software. In addition, increasing adoption of in-vitro diagnostic systems with analyzer software at diagnostic centers is anticipated to fuel market growth during the forecast period 2021-2026.
Cancer IVD Market Segment Analysis - By End Users
On the basis of end use, hospitals segment accounted for the largest segmental revenue of the Cancer IVD market in 2020 as there is an increase in hospitalization as doctors require diagnostic interpretation for further treatment of cancer. Diagnostic centers often partner with hospitals; as a result, hospitals often have their own diagnostic setup. Furthermore, ongoing healthcare infrastructure growth is projected to boost current hospital facilities. The market for cancer in-vitro diagnostic tests in hospitals is developing.
On the other hand, patient self-testing segment is projected to dominate over 2021-2026 with a CAGR of 6.50%. The patient self-testing are to witness a healthy growth owing to the rising geriatric population and increasing demand for home care in vitro diagnostic devices. Moreover, convenient and supportive care provided at home by licensed healthcare professionals also reduces hospital visits. All these factors are to drive the segmental market growth.
Cancer IVD Market Segment Analysis - By Geography
North America is the major region dominating the Cancer IVD market with a market share of 35.60% in the year 2020. This can be attributed to the use of advanced technologies and IVD methods are increasing the number of total surgeries performed in this region, the local presence of global players, and FDA approval for non-invasive surgeries in North America have fueled the regional market. Moreover, with recent developments in in-vitro diagnostics surgeries, special devices are designed for cancer treatment. Hence, it has become the responsibility of surgeons to acquire prerequisite knowledge of these devices thereby, indirectly driving regional market growth.
During the forecast period 2021-2026, however, Asia-Pacific is anticipated to be the fastest region. Asia Pacific consists of developing and developed economies. The industry is forecast to be fueled by increasing healthcare awareness and patients seeking early diagnosis in the area, as well as a high prevalence of chronic diseases. Apart from these, the rising affordability rates and improving regulatory scenario are estimated to propel the market in the region.
Cancer IVD Market Drivers
Rising Prevalence Of Cancer Coupled With Increasing Product Approvals And Product Launches
Cancer IVD Market Challenges
Unfavorable Reimbursement Scenario
Buy Now
Cancer IVD Market Landscape
Acquisitions/Product Launches
- In January 2021, Illumina revealed plans to step up its cancer detection efforts by launching a new in vitro diagnostic (IVD) test and bolstering its oncology-focused companion diagnostic (CDx) collaborations—as well as plans to launch a new cloud-based bioinformatics data platform.
- In February, 2020 – Biocare Medical announced the launch of seven novel IVD IHC antibody markers for clinical diagnostics and research applications. The most recent launch focuses on several immuno-oncology markers, critical in aiding early-stage cancer drug developments and patient treatment.
